Ten years follow-up under atorvastatin therapy of patients with carotid artery stenosis: the prognostic impact of oxidised low-density lipoprotein on carotid plaque progression and restenosis. : Atorvastatin and oxidized LDL in carotid artery stenosis

δείτε την πρωτότυπη σελίδα τεκμηρίου
στον ιστότοπο του αποθετηρίου του φορέα για περισσότερες πληροφορίες και για να δείτε όλα τα ψηφιακά αρχεία του τεκμηρίου*



Ten years follow-up under atorvastatin therapy of patients with carotid artery stenosis: the prognostic impact of oxidised low-density lipoprotein on carotid plaque progression and restenosis. : Atorvastatin and oxidized LDL in carotid artery stenosis (EN)

Liasis, Nikolaos
Alexopoulos, Konstantinos
Velissariou, Eleni
Filippou, Dimitris
Dimakopulos, George
Demesticha, Theano
Piagkou, Maria
Polydorou, Victoria
Protogerou, Vasilios
Skopelitis, Elias
Κougiali, Xanthula
Troupis, Theodoros
Polydorou, Adamantia

info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion

2022-06-24


Background: Atorvastatin reduces oxidized low-density lipoprotein (oxLDL) levels and reduces the rate of plaque progression in patients with and without prior carotid angioplasty. The aim of our study was to investigate the durability of this effect and to explore possible prognostic impact of oxLDL levels on carotid stenosis and plaque stability. Methods: 106 patients (71 males, mean age 64.82±7.26 years) were studied. They were divided into two groups. Group 1 including patients with carotid stenosis >70% (n=50) who underwent carotid angioplasty prior to enrolment. Group 2 included those with <70% stenosis who were treated medically and were given atorvastatin with dose adjusted to maintain LDL cholesterol <100mg/dl. Anthropometrics, complete lipid profile, oxLDL and ultrasonography were performed at baseline, 1, 3, 6, 12 months and yearly thereafter for 10 years. Results: oxLDL levels significantly decreased from 53.3±10.91 mg/dl at baseline to 8.31±2.08 mg/dl at 12 months (p<0.001) and remained stable until the 10th year. In group 1, restenosis (>70%) was noticed in four patients, yet no further intervention was needed due to plaque morphology (echo-grade IV). In group 2, carotid stenosis was initially reduced (6th month – 4th year) and later relapsed (5th – 10th year), yet plaque morphology was recorded as type III or IV in almost all patients of group 2 (53=95%), indicating a significantly lower risk for stroke. Conclusion: Atorvastatin treatment to a target of LDL <100 mg/dl in patients with carotid stenosis is associated with marked and durable reduction of lipid levels, especially oxLDL and LDL and reduction in the rate of stenosis progression, improved plaque stability and decreased stroke risk. (EN)


atheromatosis (EN)
carotid stenosis (EN)
atorvastatin (EN)
oxidize LDL (EN)
angioplasty (EN)

Αγγλική γλώσσα

Kalangos Foundation (EN)


2944-943X
2944-9782
Journal of Humanitarian Cardiovascular Medicine; Vol. 1 No. 1 (2022): 1st Issue (EN)

https://creativecommons.org/licenses/by-nc-sa/4.0/
Copyright (c) 2022 Journal of Humanitarian Cardio Vascular Medicine (EN)




*Η εύρυθμη και αδιάλειπτη λειτουργία των διαδικτυακών διευθύνσεων των συλλογών (ψηφιακό αρχείο, καρτέλα τεκμηρίου στο αποθετήριο) είναι αποκλειστική ευθύνη των αντίστοιχων Φορέων περιεχομένου.